Copyright
©The Author(s) 2024.
World J Obstet Gynecol. Dec 6, 2024; 13(1): 100776
Published online Dec 6, 2024. doi: 10.5317/wjog.v13.i1.100776
Published online Dec 6, 2024. doi: 10.5317/wjog.v13.i1.100776
Table 1 Baseline characteristic of the study population, n (%)
Characteristics | Non-GDM (n = 81) | Diet-treated GDM (n = 25) | Insulin-treated GDM (n = 3) | P value |
Maternal age in years | 29.37 ± 4.29 | 31.52 ± 4.67 | 30.67 ± 4.04 | 0.10 |
Parity | 0.07 | |||
Nulliparity | 43 (53.75) | 9 (36.00) | 0 (0.00) | |
Multiparity | 38 (46.91) | 16 (64.00) | 3 (100.00) | |
Risk factor | ||||
Pre-pregnancy body mass index in kg/m2 | 21.88 (19.61-25.51) | 22.00 (19.83-27.05) | 20.00 (17.67-34.22) | 0.96 |
Previous > 4000 g | 1 (1.23) | 0 | 0 | > 0.99 |
Previous GDM (n = 8) | 1 (1.23) | 1 (4.00) | 0 | 0.45 |
1st degree relative diabetes mellitus | 15 (18.51) | 4 (16.00) | 2 (66.67) | 0.15 |
Table 2 Pregnancy outcomes, n (%)
Outcomes | Non-GDM (n = 81) | Diet-treated GDM (n = 25) | Insulin-treated GDM (n = 3) | P value |
Gestational age at delivery in weeks | 39 (38-39) | 38 (38-39) | 38 (33-40) | 0.780 |
Birth weighting | 3120 (2880-3320) | 3050 (2970-3210) | 2630 (1580-3090) | 0.150 |
Placental weighting | 580.16 ± 136.85 | 566.67 ± 119.34 | 410 ± 101.49 | 0.098 |
Fetal sex | > 0.990 | |||
Male | 40 (49.38) | 13 (52.00) | 1 (33.33) | |
Female | 41 (50.62) | 12 (48.00) | 2 (66.67) | |
Apgar score | ||||
5-minute | 9 (8-9) | 9 (8-9) | 9 (9-9) | 0.700 |
10-minute | 10 (9-10) | 10 (9-10) | 10 (10-10) | 0.800 |
Pre-eclampsia | 7 (8.64) | 2 (8.00) | 0 | > 0.990 |
Weight at delivery in kg | 68.00 (61.30-76.00) | 67.70 (58.00–82.50) | 70.00 (69.60-80.70) | 0.640 |
Weight gain during pregnancy in kg | 13.00 (10.00-17.00) | 11.40 (8.70-14.00) | 13.60 (3.70-19.00) | 0.480 |
Table 3 Chemical profiles of the study population, n (%)
Chemical profiles | Non-GDM (n = 81) | Diet-treated GDM (n = 25) | Insulin-treated GDM (n = 3) | P value |
1st visit | ||||
GA in weeks | 12.00 (12.00-13.00) | 12.00 (12.00-13.00) | 12.00 (12.50-13.00) | 0.800 |
Fasting glucose in mg/dL | 77.0 (71-81) | 78 (76-81) | 98.5 (NA-NA) | 0.190 |
Fasting insulin in μU/mL | 7.74 (5.78–10.61) | 8.64 (4.83–12.78) | 11.71 (NA-NA) | 0.480 |
HOMA-IR | 1.52 (1.14–2.06) | 1.65 (0.84-2.56) | 4.49 (NA-NA) | 0.320 |
HOMA-IR ≥ 2 | 10 (12.34) | 4 (16.00) | 1 (33.33) | 0.320 |
2nd visit | ||||
GA in weeks | 16 (16-17) | 16 (16-17) | 17 (17-17) | 0.320 |
Fasting glucose in mg/dL | 74.00 (68.50-77.00) | 72.50 (69.50-77.50) | 79.00 (72.00-110.00) | 0.007 |
Fasting insulin in μU/mL | 6.96 (5.10-11.82) | 7.82 (5.73-10.05) | 8.15 (4.85-15.98) | 0.930 |
HOMA-IR | 1.23 (0.91-2.29) | 1.44 (1.04-1.74) | 1.59 (0.86-4.34) | 0.840 |
HOMA-IR ≥ 2 | 20 (24.69) | 5 (20.00) | 1 (33.33) | 0.600 |
Fibroblast growth factor 21 in pg/mL | 63.59 (54.56-75.57) | 62.94 (56.97-69.26) | 73.58 (57.28–88.85) | 0.730 |
3rd visit | ||||
GA in weeks | 25 (24-26) | 25 (25-27) | 26 (NA-NA) | 0.230 |
Fasting glucose in mg/dL | 72 (680-76) | 74 (66-79) | 71 (NA-NA) | 0.350 |
Fasting insulin in μU/mL | 9.92 (6.39-14.85) | 9.55 (5.31-20.29) | 13.2 (NA-NA) | 0.870 |
HOMA-IR | 1.69 (1.10–2.53) | 1.79 (0.82–3.97) | 2.57 (NA-NA) | 0.680 |
HOMA-IR ≥ 2 | 25 (30.86) | 8 (32.00) | 1 (33.33) | 0.660 |
Table 4 Fibroblast growth factor 21 by quintile and selected pregnancy outcomes
Outcomes | Quintile of fibroblast growth factor 21 in pg/mL | P value | ||||
1: 28.52-51.91 | 2: 53.4-59.23 | 3: 60.04–67.56 | 4: 68.24–76.70 | 5: 79.21-140.55 | ||
Maternal age in years | 29.14 ± 4.56 | 30.19 ± 4.90 | 31.03 ± 4.82 | 29.05 ± 3.35 | 30.48 ± 4.17 | 0.810 |
Pre-pregnancy body mass index in kg/m2 | 22.97 (19.42–26.37) | 23.00 (20.20-26.56) | 20.50 (19.30-23.04) | 21.80 (19.57-24.00) | 22.50 (19.20-28.00) | 0.370 |
Fasting glucose in mg/dL | 77.50 (73.00-80.50) | 79.50 (73.00-81.00) | 76.50 (74.00-82.0) | 77.50 (70.00-82.00) | 78.50 (77.00-81.00) | 0.990 |
Fasting insulin in μU/mL | 8.57 (5.09-14.50) | 9.93 (9.14-10.61) | 7.76 (5.26-10.27) | 5.08 (4.77-7.65) | 8.89 (7.08-14.66) | 0.200 |
Gestational diabetes mellitus | 4 (19.05) | 7 (33.33) | 8 (38.10) | 4 (19.05) | 5 (23.81) | 0.520 |
Pre-eclampsia | 0 (0.00) | 3 (14.29) | 2 (9.52) | 1 (4.76) | 2 (9.52) | 0.630 |
Birth weighting | 3210 (295-3295) | 3120 (2970-3380) | 3060 (2820-3140) | 3130 (2870-3335) | 3025 (2890-3260) | 0.400 |
Placental weighting | 577.14 ± 94.01 | 608.89 ± 113.70 | 552.94 ± 97.52 | 555 ± 140.76 | 567.22 ± 196.79 | 0.740 |
- Citation: Traisrisilp K, Apaijai N, Waisayanand N, Chattipakorn S. Serum fibroblast growth factor 21: Lack of association with gestational diabetes and pregnancy outcomes. World J Obstet Gynecol 2024; 13(1): 100776
- URL: https://www.wjgnet.com/2218-6220/full/v13/i1/100776.htm
- DOI: https://dx.doi.org/10.5317/wjog.v13.i1.100776